Key Points
- Insider purchase: Director Mark Christopher Capone bought 1,301 shares at $76.35 (~$99,331), boosting his stake 61.14% to 3,429 shares (~$261,804), part of multiple recent insider buys that signal management confidence.
- Valuation and dividend risks: Mesa trades at a high PE (~114) with a market cap of ~$404M and recently beat earnings, but a 100% payout ratio, 0.9% yield and a consensus "Reduce" rating raise concerns about valuation and dividend sustainability.
- CEO transition: The company named Siddhartha Kadia as President & CEO, a material leadership change that could create short‑term volatility as investors evaluate the new strategic direction.
Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) Director Mark Christopher Capone purchased 1,301 shares of the company's stock in a transaction dated Tuesday, March 10th. The stock was bought at an average price of $76.35 per share, with a total value of $99,331.35. Following the completion of the transaction, the director directly owned 3,429 shares of the company's stock, valued at approximately $261,804.15. This represents a 61.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Mesa Laboratories Price Performance
NASDAQ:MLAB opened at $73.23 on Wednesday. Mesa Laboratories, Inc. has a one year low of $55.45 and a one year high of $131.20. The stock has a market cap of $404.23 million, a PE ratio of 114.42 and a beta of 0.85. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.45 and a current ratio of 1.94. The stock has a 50 day moving average price of $87.36 and a 200 day moving average price of $78.20.
Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The medical instruments supplier reported $3.07 earnings per share for the quarter, topping analysts' consensus estimates of $2.41 by $0.66. Mesa Laboratories had a return on equity of 22.02% and a net margin of 1.51%.The company had revenue of $65.13 million for the quarter, compared to analyst estimates of $63.23 million. Equities research analysts expect that Mesa Laboratories, Inc. will post 8 EPS for the current fiscal year.
Mesa Laboratories Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Stockholders of record on Saturday, February 28th will be given a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $0.64 annualized dividend and a dividend yield of 0.9%. Mesa Laboratories's payout ratio is presently 100.00%.
Key Mesa Laboratories News
Here are the key news stories impacting Mesa Laboratories this week:
- Positive Sentiment: Multiple insider purchases by board members and directors signal insider confidence — Director Shiraz Shabanali Ladiwala bought 3,500 shares at ~$72.23 (now owns 8,523 shares), Director R. Tony Tripeny bought 1,315 shares at ~$76.00, and Director Mark Capone bought 1,301 shares at ~$76.35; these transactions materially increased their holdings and can be read as a bullish signal from management-level insiders. Read More. • SEC filings: Read More., Read More., Read More.
- Neutral Sentiment: CEO transition announced — Mesa named Siddhartha Kadia as President & CEO (succession from long‑time CEO Gary Owe). Leadership change is material and may create short‑term volatility while investors evaluate new strategic direction and execution risk, but outcome depends on Kadia’s plan and communication. Read More.
- Negative Sentiment: Recent analyst coverage and bearish commentary add downward pressure — a Seeking Alpha piece frames the company as overvalued/attracting skepticism, and MarketBeat summaries show mixed analyst views (some sells/reduces and a consensus labeled “Reduce”), plus a high P/E and a 100% payout ratio on dividends that raise valuation and sustainability concerns. These viewpoints increase selling pressure amid uncertainty. Read More. • MarketBeat summary
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on MLAB shares. Wall Street Zen raised shares of Mesa Laboratories from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 7th. Wells Fargo & Company increased their price target on shares of Mesa Laboratories from $83.00 to $94.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 4th. Zacks Research raised shares of Mesa Laboratories from a "strong sell" rating to a "hold" rating in a research report on Friday, January 9th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Mesa Laboratories in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Mesa Laboratories presently has a consensus rating of "Reduce" and an average target price of $94.00.
Read Our Latest Report on Mesa Laboratories
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of MLAB. Northwestern Mutual Wealth Management Co. boosted its stake in Mesa Laboratories by 5,366.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier's stock worth $26,000 after buying an additional 322 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Mesa Laboratories in the 4th quarter valued at approximately $27,000. Farther Finance Advisors LLC raised its stake in shares of Mesa Laboratories by 17,733.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 535 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 532 shares during the period. CWM LLC lifted its holdings in shares of Mesa Laboratories by 48.9% in the 3rd quarter. CWM LLC now owns 597 shares of the medical instruments supplier's stock worth $40,000 after acquiring an additional 196 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in shares of Mesa Laboratories in the 4th quarter worth approximately $55,000. Institutional investors and hedge funds own 90.60% of the company's stock.
About Mesa Laboratories
(
Get Free Report)
Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.
The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
